Building Global Tech from Europe: The VC Playbook

Building Global Tech from Europe: The VC Playbook

What does it take to turn a two-person startup in Paris into a $6.8 billion exit, and then do it all over again for 200 other founders? In this episode of Decoded, Dr. Jurgi Camblong speaks with Bernard Liautaud, co-founder of BusinessObjects and Managing Partner at Balderton Capital, one of Europe's leading venture capital firms backing category-defining companies like Revolut, Wayve, and Quantum Systems. Bernard didn't just build a company. He built a category. Starting with two people in Paris in 1990, he helped define what business intelligence could be, took the company to NASDAQ, and sold it to SAP for $6.8 billion. Then he turned that experience into fuel for the next generation of European founders. You'll hear why Europe's VC returns have quietly outperformed the US, how Balderton evaluates founders and the one trait they call "insurgency," what the story of Revolut reveals about the power of execution, why Bernard believes Europe has not just the talent but the values to build AI responsibly, and the philosophy behind his most personal insight: as a VC, you have many shots. As a founder, you have one. This episode is about what happens when ambition meets experience, and why Europe's most exciting chapter may still be ahead of us.

How to Accelerate the Future of Oncology with Keith Flaherty, President of the AACR

What happens when a world-class biologist decides that academic research isn't moving fast enough for patients?  Dr. Keith Flaherty is a physician, scientist, and founder who obsesses over the "wiring of cells". As the Director of Clinical Research at the Mass General Hospital Cancer Center and a Professor of Medicine at Harvard Medical School, he has authored over 300 peer-reviewed research publications. But he didn't stop at academia. He went on to co-found Loxo Oncology and Scorpion Therapeutics, driving billions in acquisitions and fundamentally changing precision cancer care.  In this episode, Keith joins Dr. Jurgi Camblong to discuss his journey from early cell biology to becoming president of the AACR. They explore the evolution of melanoma treatments, the mechanics of targeted inhibitors, and the friction in the system that prevents us from learning from every patient.  Because better outcomes don’t come from better science alone. They come from making the whole system work.  #Oncology #PrecisionMedicine #AACR #DrugDevelopment #DecodedPodcast

From Mars Rovers to Medicine: The AI Revolution with Thomas Fuchs, Chief AI Officer, Eli Lilly

What happens when the mind behind the Mars Rovers turns its attention to fighting cancer and developing next-generation medicines? Today, Thomas Fuchs is the Chief AI Officer at Eli Lilly & Company, but he started his career at NASA, building the AI that helped rovers navigate the surface of Mars. He soon realized that the same math used to distinguish sand from rocks could be used to identify cancer cells on a pathology slide. He transitioned to healthcare, coined the term "computational pathology", and secured the first-ever FDA approval for an AI solution in cancer pathology after founding Paige.ai. In this episode, Thomas joins Dr. Jurgi Camblong to discuss his journey, including how to build trust around AI, the massive potential of the technology for medicine discovery, and what the future holds for medicine. Because better outcomes don’t come from better algorithms alone—they come from pioneers brave enough to trust them. For more information on this episode follow the link below: https://www.linkedin.com/in/jurgicamblong/ [https://www.buzzsprout.com/2512908/episodes/18822592] https://www.sophiagenetics.com/podcasts/ [https://www.sophiagenetics.com/podcasts/] #AIinHealthcare #DrugDiscovery #GenerativeAI #EliLilly #DecodedPodcast

The Tumor Hacker: How Data & AI Are Rewriting the Future of Oncology

Most doctors look at a tumor and see a disease. Professor Olivier Michielin sees a code waiting to be cracked.  Starting his career in physics and training under Nobel Prize winner Martin Karplus, Olivier realized early on that he "would not be happy just talking to electrons". He pivoted to medicine to bring a data-driven, engineering mindset to oncology. Today, he is rewriting the rules of how we treat melanoma and other complex cancers by combining immunotherapy with advanced algorithms.  In this episode, the "Tumor Hacker" joins Dr. Jurgi Camblong to discuss how he is using physics, AI, and immunotherapy to rewrite the future of oncology. From training with Nobel laureates to leading oncology at HUG, Olivier explains why the future of medicine isn’t about discovering cures by accident - it’s about engineering them by design.  A conversation about the convergence of data, biology, and the human immune system.  For more information on this episode follow the link below: https://www.linkedin.com/in/jurgicamblong/ [https://www.linkedin.com/in/jurgicamblong/] https://www.sophiagenetics.com/podcasts/ [https://www.sophiagenetics.com/podcasts/] #Oncology #Immunotherapy #AIinHealthcare #PrecisionMedicine #DecodedPodcast

Decoding Human Health: Stanford’s Michael Snyder on Aging, AI, and the Next Era of Precision Care

Are we practicing healthcare, or just "sick care"? In this episode of Decoded, Jurgi Camblong sits down with Dr. Michael Snyder, Chair of Genetics at Stanford Medicine and one of the most cited scientists in the world, to challenge the status quo of modern medicine. We monitor our cars with dashboards to prevent breakdowns, yet we wait until our bodies fail before seeking help. Dr. Snyder explains why the future of medicine isn't about treating illness—it's about predicting it. In this episode, we cover: The "Sick Care" Crisis: Why our current system is designed to fail and how to fix it. The Body Dashboard: Using big data, AI, and wearables to monitor health in real-time. Redefining Aging: How deep metabolic profiling can help us live longer, healthier lives. The Future of Diagnostics: Moving from reactive treatments to proactive precision care. Tune in to hear how data is rewriting the rules of human longevity.